• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aditxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    5/19/25 5:12:30 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email
    false 0001726711 0001726711 2025-05-16 2025-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 16, 2025

     

    Aditxt, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39336   82-3204328
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2569 Wyandotte Street, Suite 101, Mountain View, CA   94043
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 870-1200

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425 )
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   ADTX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On May 16, 2025, Aditxt, Inc. (the “Company”) hosted a weekly update featuring Amro Albanna, the Chief Executive Officer of the Company and Jeff Ramson, CEO of PCG Advisory. A copy of the transcript of the weekly update is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information contained in this item, including that incorporated by reference, is being furnished to the Securities and Exchange Commission. Such information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

     

    Cautionary Note on Forward-Looking Statements

     

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the “safe harbor “provisions under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Current Report on Form 8-K, including statements regarding the Company’s future results of operations and financial position are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “target,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K, and on the current expectations of the management team of the Company and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

     

    These forward-looking statements are subject to a number of risks including, but not limited to, the following risks: (1) the risk that the Company’s currently proposed transactions may not be completed in a timely manner or at all, which may adversely affect the price of the Company’s securities; (2) the failure to satisfy the conditions to the closing of the transactions, including the approval by the stockholders of the acquisition target; (3) the ability to realize the anticipated benefits of the proposed transactions; and (4) other risks and uncertainties indicated from time to time in the Company’s public filings with the SEC. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and other documents we filed, or will file with the SEC. There may be additional risks that the Company does not presently know, or that the Company currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaim any obligation to do so, except as otherwise required by law. These forward-looking statements should not be relied upon as representing the Company’s assessments of any date subsequent to the date of this Current Report on Form 8-K. Accordingly, undue reliance should not be placed upon the forward-looking statements.

     

    Disclaimer:

     

    The information contained in the transcript furnished as Exhibit 99.1 is a textual representation of an audio recording of the weekly update and while efforts are made to provide an accurate transcription, there may be material errors, omissions or inaccuracies in the reporting of the substance of the audio recording. The Company does not assume any responsibility for any investment or other decisions made based upon the information provided in this transcript. Users are advised to review the audio recording and the Company’s SEC filings before making any investment or other decisions. An archived recording of the weekly update will be available for 30 days on the “Investor Relations” section of the Company’s website at www.aditxt.com.

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit No.   Exhibit
    99.1   Transcript of Weekly Update – May 16, 2025
    104   Cover Page Interactive Data File (embedded within the XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 19, 2025

     

      Aditxt, Inc.
         
      By: /s/ Amro Albanna
      Name:   Amro Albanna
      Title: Chief Executive Officer

     

     

    3

     
    Get the next $ADTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADTX
    SEC Filings

    See more
    • Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      6/9/25 4:21:42 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      6/2/25 4:30:07 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      5/27/25 6:10:14 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

      -- BV Market Projected to Reach $1.0 Billion in the U.S. by 2033 -- -- BV Affects 21 Million U.S. Women; As many as 50% Experience Recurrent BV Within Six Months of Treatment -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent bacterial vaginosis (BV) presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting supports further development of SOLOSEC for the management of recurrent BV, a potential new indication. EVFM) (PRNews

      6/11/25 8:14:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow's Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences' CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women's health, respectively. Event Details: Title: Aditxt Weekly Update Date: Friday, June 6, 2025 Time: 11:30 a.m. ET Location: Virtual (Zoom) Registration: Click here to register Friedrich Kapp, M.D, Ph.D. is co-CEO of Adimune, Inc.("Adimune"), which is advancing its lead therapeutic candidate ADI-100™ towards an Investigational New Dru

      6/5/25 8:15:00 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/14/24 2:14:47 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/6/24 10:06:47 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      1/2/24 3:10:18 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Financials

    Live finance-specific insights

    See more
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

      — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

      11/14/24 4:36:00 PM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

      — Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

      8/14/24 7:00:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - Aditxt, Inc. (0001726711) (Issuer)

      6/9/25 5:56:40 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hrt Financial Lp claimed ownership of 25,434 units of Class A Shares (SEC Form 3)

      3 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:31:48 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on ADiTx Therapeutics

      Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy

      2/4/21 8:32:09 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

      Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in

      4/2/25 8:17:20 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care